Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
Björn PasternakPeter UedaBjörn EliassonAnn-Marie SvenssonStefan FranzénSoffia GudbjörnsdottirKristian HveemChristian JonassonViktor WintzellMads MelbyeHenrik SvanströmPublished in: BMJ (Clinical research ed.) (2019)
In this large Scandinavian cohort, SGLT2 inhibitor use compared with DPP4 inhibitor use was associated with reduced risk of heart failure and any cause death, but not with major cardiovascular events in the primary intention-to-treat analysis. In the additional as-treated analyses, the magnitude of the association with heart failure and any cause death became larger, and a reduced risk of major cardiovascular events that was largely driven by the cardiovascular death component was observed. These data help inform patients, practitioners, and authorities regarding the cardiovascular effectiveness of SGLT2 inhibitors in routine clinical practice.
Keyphrases
- cardiovascular events
- heart failure
- coronary artery disease
- clinical practice
- cardiovascular disease
- end stage renal disease
- newly diagnosed
- left ventricular
- chronic kidney disease
- randomized controlled trial
- cardiac resynchronization therapy
- acute heart failure
- ejection fraction
- primary care
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- type diabetes
- electronic health record
- big data
- machine learning
- general practice
- artificial intelligence